Thor Medical to supply Thorium-228 for Oncoinvent's Radspherin® phase 3 program

Thor Medical ASA and Oncoinvent ASA have signed a strategic agreement for Thorium-228 radioisotopes, crucial for Oncoinvent's lead product candidate, Radspherin®, as it progresses to phase 3 clinical trials. Thor Medical will supply Thorium-228 from its AlphaOne manufacturing plant. This material serves as the starting point for Radium-224, the key radioisotope in Radspherin®, which directly targets cancers in body cavities. Oncoinvent is currently in a randomized phase 2 trial for peritoneal carcinomatosis from ovarian cancer.

This agreement is vital for Oncoinvent's planned phase 3 program for peritoneal metastases from ovarian cancer, ensuring the availability of Thorium-228 within Norway's growing radiopharmaceutical sector. Thor Medical highlights the increasing demand for sustainable alpha-emitters and its role in Oslo's vibrant radiopharmaceutical cluster. Both companies are headquartered in Oslo.

Oncoinvent's Radspherin® utilizes radium-224 to target micro-metastases post-surgery, with ongoing phase 1 and 2 trials in ovarian cancer and a finalized phase 1/2a trial in colorectal cancer. Thor Medical specializes in producing alpha particle emitters from naturally occurring thorium, utilizing a proprietary process that avoids nuclear reactors and provides an environmentally friendly supply chain.